Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza drug in Japan. Additionally, favipiravir is being stockpiled for 2 million people as a countermeasure for novel influenza strains. This drug functions as a chain terminator at the site of incorporation of the viral RNA and reduces the viral load. Favipiravir cures all mice in a lethal influenza infection model, while oseltamivir fails to cure the animals. Thus, favipiravir contributes to curing animals with lethal infection. In addition to influenza, favipiravir has a broad spectrum of anti-RNA virus activities in vitro and efficacies in animal models with lethal RNA viruses and has been used for treatment of human infection with life-threatening Ebola virus, Lassa virus, rabies, and severe fever with thrombocytopenia syndrome. The best feature of favipiravir as an antiviral agent is the apparent lack of generation of favipiravir-resistant viruses. Favipiravir alone maintains its therapeutic efficacy from the first to the last patient in an influenza pandemic or an epidemic lethal RNA virus infection. Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available.

中文翻译：

---

Favipiravir，一种抗威胁生命的RNA病毒感染的抗流感药物。

Favipiravir已开发为抗流行性感冒药物，并在日本获得许可用作抗流行性感冒药物。此外，正在为200万人储备favipiravir，作为新型流感病毒株的对策。该药物在病毒RNA的结合位点起链终止剂的作用，并降低了病毒载量。法维拉韦可以治愈致命流感感染模型中的所有小鼠，而奥司他韦则不能治愈动物。因此，favipiravir有助于治愈具有致命感染的动物。除流感外，favipiravir在体外具有广泛的抗RNA病毒活性，并在具有致命RNA病毒的动物模型中具有功效，已被用于治疗威胁生命的埃博拉病毒，拉沙病毒，狂犬病和重症人类感染血小板减少综合征发烧。法维吡韦作为抗病毒药物的最大特点是明显缺乏耐法维吡韦的病毒的产生。在流感大流行或流行性致死性RNA病毒感染中，单独使用Favipiravir可以保持从第一位到最后一位患者的治疗效果。Favipiravir有望成为重症流感，下一个大流行性流感毒株和其他无法进行标准治疗的重症RNA病毒感染的重要治疗剂。